RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

Core Insights - RAPT Therapeutics has appointed Dr. Jessica Savage as Vice President of Clinical Development to lead the development of RPT904, a monoclonal antibody targeting free human immunoglobulin E (IgE) for allergic diseases [1][2] - The company plans to initiate a Phase 2b clinical trial for RPT904 in food allergy in the second half of 2025, aiming to address a significant unmet need in this area [2][3] Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases, leveraging proprietary expertise in immunology [4] Leadership and Expertise - Dr. Jessica Savage brings extensive experience in clinical development, particularly in food allergy, having held significant roles at prestigious institutions and companies [3] - Her previous experience includes leading clinical development strategies for various therapies at Alexion and contributing to multiple New Drug Applications (NDAs) at other pharmaceutical companies [3]